Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

ADXS-503 for Metastatic Squamous and NSCLC - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if the study drugs (ADXS-503 and Pembrolizumab) are safe to give, and whether they are useful therapies for non-small cell lung cancer.
What is the Condition Being Studied?
Non Small Cell Lung Cancer (NSCLC)

Who Can Participate in the Study?

Adults 18 and older with NSCLC

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
-Be in the study for up to 24 months
-Get chemotherapy and immunotherapy
-Give blood samples
-Possibly give a small sample of lung tissue
-Complete regular care with your doctor

Study Details

Full Title
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00101139
NCT: NCT03847519
Phase
Phase I/II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698